UTHRUnited Therapeutics Corporation

$24B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$609M+18.1% YoY

Gross Profit

$539M88.5% margin

Operating Income

$327M53.7% margin

Net Income

$268M43.9% margin

EPS (Diluted)

$5.38

QoQ Revenue Growth

+2.2%

Cash Flow

Operating Cash Flow

$346M

Free Cash Flow

$281M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$7.0B

Total Liabilities

$1.3B

Stockholders' Equity

$5.7B

Cash & Equivalents

$1.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$609M	$516M	+18.1%
Gross Profit	$539M	$479M	+12.6%
Operating Income	$327M	$314M	+4.0%
Net Income	$268M	$239M	+11.8%

Revenue Segments

Tyvaso

$205M34%

Remodulin

$131M22%

Tyvaso Member

$121M20%

Orenitram

$92M15%

Unituxin

$51M8%

Adcirca

$7M1%

Product and Service, Other

$2M0%

Geographic Segments

UNITED STATES

$585M96%

Non-US

$25M4%

UTHR Q3 2023 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena